Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Marais, R

Class:IdPerson:1497943
_displayNameMarais, R
_timestamp2011-08-17 14:10:05
created[InstanceEdit:1497942] Rothfels, K, 2011-08-17
firstnameRichard
initialR
surnameMarais
(author)[LiteratureReference:1497944] The RAF proteins take centre stage
[LiteratureReference:5672176] ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf
[LiteratureReference:5672195] Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
[LiteratureReference:5672205] MEK kinase activity is not necessary for Raf-1 function
[LiteratureReference:5672236] Mutations of the BRAF gene in human cancer
[LiteratureReference:5672291] Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization
[LiteratureReference:5672435] Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases
[LiteratureReference:5672469] Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
[LiteratureReference:5672542] Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation
[LiteratureReference:6790348] In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling
List all 16 refering instances
[Change default viewing format]
No pathways have been reviewed or authored by Marais, R (1497943)